These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25998051)

  • 41. Targeted delivery system using silica nanoparticles coated with chitosan and AS1411 for combination therapy of doxorubicin and antimiR-21.
    Khatami F; Matin MM; Danesh NM; Bahrami AR; Abnous K; Taghdisi SM
    Carbohydr Polym; 2021 Aug; 266():118111. PubMed ID: 34044928
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment.
    Liang X; Wang Y; Shi H; Dong M; Han H; Li Q
    Int J Nanomedicine; 2021; 16():2569-2584. PubMed ID: 33833512
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
    Taverna JA; Hung CN; DeArmond DT; Chen M; Lin CL; Osmulski PA; Gaczynska ME; Wang CM; Lucio ND; Chou CW; Chen CL; Nazarullah A; Lampkin SR; Qiu L; Bearss DJ; Warner S; Whatcott CJ; Mouritsen L; Wade M; Weitman S; Mesa RA; Kirma NB; Chao WT; Huang TH
    Cancer Res; 2020 Apr; 80(7):1551-1563. PubMed ID: 31992541
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.
    Boshuizen J; Pencheva N; Krijgsman O; Altimari DD; Castro PG; de Bruijn B; Ligtenberg MA; Gresnigt-Van den Heuvel E; Vredevoogd DW; Song JY; Visser N; Apriamashvili G; Janmaat ML; Plantinga TS; Franken P; Houtkamp M; Lingnau A; Jure-Kunkel M; Peeper DS
    Cancer Res; 2021 Apr; 81(7):1775-1787. PubMed ID: 33531370
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer.
    Mudduluru G; Ceppi P; Kumarswamy R; Scagliotti GV; Papotti M; Allgayer H
    Oncogene; 2011 Jun; 30(25):2888-99. PubMed ID: 21317930
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Axl-148b chimeric aptamers inhibit breast cancer and melanoma progression.
    Quirico L; Orso F; Esposito CL; Bertone S; Coppo R; Conti L; Catuogno S; Cavallo F; de Franciscis V; Taverna D
    Int J Biol Sci; 2020; 16(7):1238-1251. PubMed ID: 32174798
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target.
    Paccez JD; Vasques GJ; Correa RG; Vasconcellos JF; Duncan K; Gu X; Bhasin M; Libermann TA; Zerbini LF
    Oncogene; 2013 Feb; 32(6):689-98. PubMed ID: 22410775
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia.
    Zhao N; Pei SN; Qi J; Zeng Z; Iyer SP; Lin P; Tung CH; Zu Y
    Biomaterials; 2015 Oct; 67():42-51. PubMed ID: 26204224
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current progress on aptamer-targeted oligonucleotide therapeutics.
    Dassie JP; Giangrande PH
    Ther Deliv; 2013 Dec; 4(12):1527-46. PubMed ID: 24304250
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
    Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S
    Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stick-Based Methods for Aptamer-Mediated siRNA Targeted Delivery.
    Catuogno S; Esposito CL; Giangrande PH
    Methods Mol Biol; 2021; 2282():31-42. PubMed ID: 33928568
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
    Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG
    Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cell-specific aptamer-mediated targeted drug delivery.
    Zhou J; Rossi JJ
    Oligonucleotides; 2011 Feb; 21(1):1-10. PubMed ID: 21182455
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multifunctional nucleic acids for tumor cell treatment.
    Pofahl M; Wengel J; Mayer G
    Nucleic Acid Ther; 2014 Apr; 24(2):171-7. PubMed ID: 24494617
    [TBL] [Abstract][Full Text] [Related]  

  • 56. AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.
    Balaji K; Vijayaraghavan S; Diao L; Tong P; Fan Y; Carey JP; Bui TN; Warner S; Heymach JV; Hunt KK; Wang J; Byers LA; Keyomarsi K
    Mol Cancer Res; 2017 Jan; 15(1):45-58. PubMed ID: 27671334
    [TBL] [Abstract][Full Text] [Related]  

  • 57. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
    Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
    J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Smart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapy.
    Aaldering LJ; Tayeb H; Krishnan S; Fletcher S; Wilton SD; Veedu RN
    RNA Biol; 2015; 12(4):412-25. PubMed ID: 25849197
    [TBL] [Abstract][Full Text] [Related]  

  • 59. First Axl inhibitor enters clinical trials.
    Sheridan C
    Nat Biotechnol; 2013 Sep; 31(9):775-6. PubMed ID: 24022140
    [No Abstract]   [Full Text] [Related]  

  • 60. Modular cell-internalizing aptamer nanostructure enables targeted delivery of large functional RNAs in cancer cell lines.
    Porciani D; Cardwell LN; Tawiah KD; Alam KK; Lange MJ; Daniels MA; Burke DH
    Nat Commun; 2018 Jun; 9(1):2283. PubMed ID: 29891903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.